Retour

Watch Compare

Quince Therapeutics, Inc.

Qualité des données : 83%

QNCX

Nasdaq Manufacturing Chemicals

0,12 €

▼ 0,06 € (-32,66%)

Cap. Boursière: 6,89 M

Prix

0,12 €

Cap. Boursière

6,89 M

Fourchette du Jour

0,12 € — 0,16 €

Fourchette 52 Semaines

0,08 € — 4,55 €

Volume

159 978 658

Ouverture 0,13 €

Moyenne 50J / 200J

0,39 €

68,02% below

Moyenne 50J / 200J

1,70 €

92,76% below

Quick Summary

Points Clés

Debt/Equity of 0,00 — conservative balance sheet

Negative free cash flow of -38,98 M

Croissance

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Qualité

Return on Equity

-890,64%

En dessous de la moyenne du secteur (-53,41%)

ROIC-41,40%

Net MarginN/A

Op. MarginN/A

Sécurité

Debt / Equity

0,00

En dessous de la moyenne du secteur (0,31)

Current Ratio1,12

Interest CoverageN/A

Valorisation

PE (TTM)

-0,12

Au-dessus de la moyenne du secteur (-1,48)

P/B Ratio6,50

EV/EBITDAN/A

Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)

Métrique	Action	Médiane du Secteur
P/E	-0,1	-1,5
P/B	6,5	1,6
ROE %	-890,6	-53,4
Net Margin %	—	-41,5
Rev Growth 5Y %	—	1,8
D/E	0,0	0,3

ETFs Holding This Stock

BRSIX BRSIX

0,10% weight

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	N/A	Net Income (TTM)	-56,98 M
ROE	-890,64%	ROA	-50,18%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-38,98 M
ROIC	-41,40%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0,00	Current Ratio	1,12
Interest Coverage	N/A	Asset Turnover	N/A
Working Capital	3,16 M	Tangible Book Value	-66,67 M
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	-0,12	Forward P/E	N/A
P/B Ratio	6,50	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-565,88%
Market Cap	6,89 M	Enterprise Value	435 800,0
Per Share
EPS (Diluted TTM)	-1,20	Revenue / Share	N/A
FCF / Share	-0,70	OCF / Share	-0,69
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	N/A	FCF Conversion	68,41%
SBC-Adj. FCF	-44,02 M	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	—	—	—	—	—
Net Income	-56,83 M	-31,39 M	-51,66 M	-89,95 M	-76,85 M
EPS (Diluted)	-1,31	-0,84	-1,54	—	—
Gross Profit	—	—	—	—	—
Operating Income	-57,29 M	-34,62 M	-52,02 M	-90,32 M	-78,89 M
EBITDA	—	—	—	—	—
R&D Expenses	18,59 M	9,45 M	25,18 M	60,80 M	61,31 M
SG&A Expenses	—	—	—	—	—
D&A	186 000,0	322 000,0	204 000,0	344 000,0	332 000,0
Interest Expense	—	—	—	—	957 000,0
Income Tax	87 000,0	197 000,0	-284 000,0	—	0,0

Balance Sheet

Annual, most recent first

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Total Assets	114,48 M	167,90 M	103,91 M	133,23 M	189,47 M
Total Liabilities	84,33 M	82,82 M	3,32 M	14,64 M	17,20 M
Shareholders' Equity	30,15 M	85,08 M	100,59 M	118,59 M	172,26 M
Total Debt	14,32 M	13,43 M	—	—	—
Cash & Equivalents	40,80 M	75,10 M	90,20 M	106,80 M	133,80 M
Current Assets	44,04 M	77,44 M	93,75 M	111,67 M	137,86 M
Current Liabilities	7,28 M	9,57 M	3,07 M	14,22 M	17,00 M